Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Diabetes and heart disease may stem from fat you can't see

Becoming fat brings conspicuous changes to the shape of the human body, but pioneering research in the Department of Medicine at Flinders University, Australia is working on the theory that the obvious "spare tyre" may not be the major culprit in fat-related diseases.

24 Aug 2004

Surprise finding could lead to hepatitis C vaccine

New research from the University of New South Wales shows some people may repeatedly be able to clear hepatitis C virus from their bodies, without any biological traces of the potentially serious infection.

23 Aug 2004

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Since the introduction of highly active combination drug therapy for HIV, liver failure attributable to infection with the hepatitis C virus (HCV) has become a leading cause of death among those infected with the virus that causes AIDS.

22 Aug 2004

British team and NASA plan to take stem cells into space

The $US1 million project aims to explore ways to protect astronauts from space radiation in preparation for a manned mission to Mars in 2020.

12 Aug 2004

Liver transplantation outcomes have significantly improved for patients with hepatitis B

Since the early 1990s, therapeutic options for patients undergoing liver transplantation for hepatitis B have evolved to include HBV immune globulin (HBIG) and lamivudine.

9 Aug 2004

Correlation between HCV viral load and severity of liver disease

The significance of hepatitis C virus (HCV) serum titers (HCV viral load) has been examined in several clinical situations. There is much evidence that patients with a lower viral load have better response rates to anti-viral therapy compared to those with higher levels.

9 Aug 2004

Self-recovery from Hep C infection linked to genes that suppress action of killer immune cells

In a study to be published in Science online Aug. 6, researchers at Johns Hopkins have found that genes involved in suppressing the body's defensive "killer" immune cells are a potential key factor in spontaneous recovery from hepatitis C.

5 Aug 2004

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

An international study with nearly 900 patients co-infected with Human Immunodeficiency Virus (HIV) and hepatitis C virus (HCV) has shown that HCV can be treated effectively and safely, without compromising the patient’s HIV therapy.

29 Jul 2004

New drug combination more effective than the previous generation of hepatitis C/HIV therapy

A new study reveals the highest efficacy rates ever reported among patients co-infected with hepatitis C and HIV treated with pegylated interferon and ribavirin.

28 Jul 2004

Roche files for application with FDA to market hepatitis C medication Pegasys(R) for chronic hepatitis B treatment

Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis B (CHB).

21 Jul 2004

Blacks receive transplants at disproportionately low rates

Black people in the United States have reduced access to many medical therapies and liver transplantation is one area where such disparity is suspected to exist.

15 Jul 2004

Rabies infections in organ donor and transplant recipients

On June 30, 2004, CDC confirmed diagnoses of rabies in three recipients of transplanted organs and in their common donor, who was found subsequently to have serologic evidence of rabies infection.

2 Jul 2004

The EU is contributing €9 million to the “Vigilance against Viral Resistance” (VIRGIL) project

Viruses’ growing resistance to drugs means diseases such as hepatitis B and C are increasingly difficult to treat. New pandemics may arise with unforeseeable consequences.

29 Jun 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004

New study to determine the effectiveness of a new pediatric screening method for Wilson's disease

Mayo Clinic seeks normal healthy children and young adults between the ages of 3 months and 18 years for a research study to determine the effectiveness of a new pediatric screening method for Wilson's disease.

7 Jun 2004

Combination treatment may help type 2 diabetes patients

New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.

6 Jun 2004

Students win awards for research into liver disease, cancer and insomnia

Targeting a range of diseases and disorders, three University of Houston students won awards at a recent symposium for research in liver disease, cancer and insomnia.

2 Jun 2004

Anemia is a major determinant of fatigue in patients with cirrhosis

Fatigue is a common complaint among patients with cirrhosis with many possible contributing factors, including severity of liver disease, anemia, and cardiopulmonary complications.

27 May 2004

Caffeinated beverages may benefit some people who are at high-risk for liver disease

According to new research presented today at Digestive Disease Week, drinking caffeinated beverages may benefit some people who are at high-risk for liver disease. Conversely, a study by researchers from India found that soda drinkers, who represent a huge percentage of the American population, may actually have an increased risk of developing esophageal cancer.

19 May 2004

Fatty liver disease (NAFLD) in obese children has distinct characteristics different from those found in adults

Potentially life-threatening non-alcoholic fatty liver disease (NAFLD) in obese children has distinct characteristics, often different from those found in adults, according to a University of California, San Diego (UCSD) School of Medicine study led by Jeffrey Schwimmer, M.D., assistant professor of pediatrics.